Non-metastatic castration-resistant prostate cancer: current status and future directions.
Ruby GuptaIris Y ShengPedro C BarataJorge A GarciaPublished in: Expert review of anticancer therapy (2020)
M0CRPC is a disease state in prostate cancer when serologic progression (PSA only disease) occurs despite castrated levels of testosterone and imaging shows no evidence of metastasis. With the availability of next-generation imaging, more patients are migrating from M0CRPC to mCRPC space. This stage migration impacts the treatment options currently available in clinical practice and requires the integration of novel imaging in prospective studies moving forward. Until that data become available men with M0CRPC should be considered for therapy with any of these three novel oral AR inhibitors, with a positive impact in metastasis-free and overall survival. Treatment selection should be based on Quality of Life, side effects, and drug-drug interactions.
Keyphrases
- prostate cancer
- high resolution
- clinical practice
- end stage renal disease
- radical prostatectomy
- chronic kidney disease
- squamous cell carcinoma
- small cell lung cancer
- stem cells
- replacement therapy
- emergency department
- fluorescence imaging
- mass spectrometry
- big data
- middle aged
- adverse drug
- cell therapy
- combination therapy